PANTHER-IPF
2012
Prednisone, Azathioprine and N-Acetylcysteine in IPF
In patients with idiopathic pulmonary fibrosis, prednisone + azathioprine + NAC increased mortality and hospitalisation compared with placebo.
Result
Efficacy: Primary: change in FVC over 60 weeks (death/hospitalisation secondary)HR 12.11 (95% CI 2.83-51.85)
Below 1 favours prednisone + azathioprine + NAC, above 1 favours placebo.
Also reported: Combination vs placebo: 8 vs 1 deaths (P=0.01), 23 vs 7 hospitalisations (P<0.001); Arm stopped early. NAC monotherapy no benefit (2014).
- Subtopic
- Immunosuppression: IPF
- Design
- Three-arm RCT, stopped early
- Enrolled
- 155 patients
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ATS/ERS 2015 IPF
- Source
- Idiopathic Pulmonary Fibrosis Clinical Research Network. N Engl J Med. 2012;366(21):1968-1977.doi 10.1056/NEJMoa1113354
Discussion & critique
Definitively ended the use of immunosuppression in IPF and reshaped guidelines.